HBM Holdings Limited has issued a positive profit alert, indicating an expected profit for the six months ending June 30, 2025, ranging from approximately US$68 million to US$74 million. This anticipated increase in profit is primarily attributed to ongoing strategic partnerships with global pharmaceutical companies, including a significant collaboration with AstraZeneca PLC. The forecast is based on a preliminary assessment of the Group's unaudited management accounts for the Reporting Period. Shareholders and potential investors are advised to exercise caution and seek professional advice when dealing in the company's securities, as the actual results may differ from this preliminary assessment. The official interim results announcement is expected to be published by the end of August 2025.